Research programme: bradykinin B2 receptor antagonists - Jerini
Alternative Names: JSM-10292Latest Information Update: 24 Mar 2010
At a glance
- Originator Jerini
- Class Small molecules
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 04 Dec 2007 This programme is still in active development
- 05 Jul 2006 Preclinical trials in Inflammation in Germany (PO)
- 05 Jul 2006 Preclinical trials in Pain in Germany (PO)